Plasma HPS concentrations were elevated in patients with nonalcoholic fatty liver disease (NAFLD) [11], diabetes [12], and hyperglycemic crisis [13], while decreased significantly in subjects with hyperglycemic crisis after standard treatment accompanied by improved hepatic functions [13]. The gene discussed is FGL1; the disease is metabolic dysfunction-associated steatotic liver disease.